XORTX Therapeutics (TSXV:XRTX) Moat Score: 2/10 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:XRTX XORTX Therapeutics Inc TSXV:XRTX
30 GF Score
Price C$2.84
! 1 Warning Sign
View Full Analysis

What is XORTX Therapeutics Moat Score?

XORTX Therapeutics TSXV:XRTX 30 Moat Score is 2 as of Aug. 02, 2026. GuruFocus rates TSXV:XRTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,394 Biotechnology companies, XORTX Therapeutics ranks better than 58.32% on this metric.

XORTX Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

XORTX Therapeutics has No Moat: XORTX Therapeutics Inc lacks significant market leadership and customer loyalty. The company does not possess strong intellectual property or regulatory barriers, and its market presence is limited, resulting in minimal competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes XORTX Therapeutics might have No Moat - Very weak/transient advantages.

XORTX Therapeutics  (TSXV:XRTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

XORTX Therapeutics Moat Score Related Terms

TSXV:XRTX vs VRTX, REGN, RVMD: Moat Score Comparison

For the Biotechnology subindustry, XORTX Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Moat Score falls into.


TSXV:XRTX
30GF Score
XORTX Therapeutics Inc TSXV:XRTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
XORTX Therapeutics (TSXV:XRTX) has a Moat Score of 2 as of Aug. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, XORTX Therapeutics ranks #581 out of 1394 companies in the Biotechnology industry, placing it in the top 41.7%.
Is XORTX Therapeutics' Moat Score too high?
XORTX Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. XORTX Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, XORTX Therapeutics ranks #581 out of 1394 companies in the Biotechnology industry, which is above the industry midpoint. Overall, XORTX Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does XORTX Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XORTX Therapeutics ranks #581 out of 1394 companies for Moat Score. This puts XORTX Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. XORTX Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XORTX Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XORTX Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XORTX Therapeutics stock overvalued right now?
XORTX Therapeutics (TSXV:XRTX) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. XORTX Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For XORTX Therapeutics (TSXV:XRTX), the current Moat Score is 2 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XORTX Therapeutics Business Description

Other Exchanges XRTX:USAANU:Germany
Address 3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
30GF Score

Get the complete analysis for TSXV:XRTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$2.84
Price